Article

Guidelines help to measure burden

There is no shortage of studies to measure the costs of visual impairment, but because the studies use a variety of approaches to analyze data, it has been difficult to draw conclusions.

There is no shortage of studies that measure the costs of visual impairment, to individuals and to specific countries.

In 2007, the Association for Research in Vision and Ophthalmology (ARVO) and the International Agency for the Prevention of Blindness convened a workshop in Vancouver, British Columbia to develop consensus on best practices for measuring the burden of vision loss.

"When estimates of the cost of visual impairment vary over time or across countries," explained lead author Kevin Frick, PhD, from Johns Hopkins University, "policy makers are left to ponder whether one estimate differs from another because of changes in the population, changes in the impact of the disease, or changes in the methods. Researchers can help policy makers by removing one of the potential variables: changes in methods."

Co-author Steven Kymes, PhD, from Washington University in St. Louis, added: "Higher-quality studies using a methodology that consistently follows guidelines will help decision makers and advocates in the ophthalmology community to [understand better] the magnitude of the impact of visual impairment, how it is likely to change with demographic changes and no additional interventions, and how additional interventions can change the impact over time."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.